G0S2 and metabolic dysfunction-associated steatotic liver disease: Inhibition of AT-lipolysis or hepatic G0S2 expression may represent an effective strategy to enhance hepatic TG catabolism thereby counteracting hepatic fat accumulation and NAFLD development.